JPWO2021108455A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021108455A5
JPWO2021108455A5 JP2022530237A JP2022530237A JPWO2021108455A5 JP WO2021108455 A5 JPWO2021108455 A5 JP WO2021108455A5 JP 2022530237 A JP2022530237 A JP 2022530237A JP 2022530237 A JP2022530237 A JP 2022530237A JP WO2021108455 A5 JPWO2021108455 A5 JP WO2021108455A5
Authority
JP
Japan
Prior art keywords
tils
population
agonist
item
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022530237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502780A (ja
JP2023502780A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/062094 external-priority patent/WO2021108455A1/en
Publication of JP2023502780A publication Critical patent/JP2023502780A/ja
Publication of JPWO2021108455A5 publication Critical patent/JPWO2021108455A5/ja
Publication of JP2023502780A5 publication Critical patent/JP2023502780A5/ja
Priority to JP2025133444A priority Critical patent/JP2025159098A/ja
Withdrawn legal-status Critical Current

Links

JP2022530237A 2019-11-25 2020-11-24 腫瘍浸潤リンパ球の活性化及び増殖方法 Withdrawn JP2023502780A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025133444A JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940035P 2019-11-25 2019-11-25
US62/940,035 2019-11-25
US202063081539P 2020-09-22 2020-09-22
US63/081,539 2020-09-22
PCT/US2020/062094 WO2021108455A1 (en) 2019-11-25 2020-11-24 Methods for activation and expansion of tumor infiltrating lymphocytes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025133444A Division JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Publications (3)

Publication Number Publication Date
JP2023502780A JP2023502780A (ja) 2023-01-25
JPWO2021108455A5 true JPWO2021108455A5 (https=) 2023-12-01
JP2023502780A5 JP2023502780A5 (https=) 2023-12-01

Family

ID=76128945

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022530237A Withdrawn JP2023502780A (ja) 2019-11-25 2020-11-24 腫瘍浸潤リンパ球の活性化及び増殖方法
JP2025133444A Pending JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025133444A Pending JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Country Status (8)

Country Link
US (1) US20240376428A1 (https=)
EP (1) EP4065233A4 (https=)
JP (2) JP2023502780A (https=)
KR (1) KR20220119038A (https=)
CN (1) CN115003387A (https=)
AU (1) AU2020392094A1 (https=)
CA (1) CA3162272A1 (https=)
WO (1) WO2021108455A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
WO2021252804A1 (en) 2020-06-12 2021-12-16 Nkarta, Inc. Genetically modified natural killer cells for cd70-directed cancer immunotherapy
CN114901805B (zh) 2020-11-19 2023-07-25 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的培养方法及其用途
CN117616115A (zh) * 2021-08-03 2024-02-27 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
WO2023039410A1 (en) * 2021-09-08 2023-03-16 KSQ Therapeutics, Inc. Lymphocyte potency assay
CN118414422A (zh) * 2021-12-30 2024-07-30 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
WO2023138598A1 (zh) * 2022-01-19 2023-07-27 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞在疾病治疗中的用途
EP4471128A4 (en) * 2022-01-29 2026-03-04 Suzhou Grit Biotechnology Co Ltd Modified tumor infiltrating lymphocyte and use thereof
CA3254363A1 (en) * 2022-03-07 2023-09-14 Nkarta, Inc. Multiplex gene-edited cells for CD70-led cancer immunotherapy
CN117417894A (zh) * 2023-09-15 2024-01-19 毕诺济(上海)生物技术有限公司 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用
WO2025092690A1 (zh) * 2023-10-30 2025-05-08 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008522951A (ja) * 2004-07-19 2008-07-03 ベイラー・カレツジ・オブ・メデイシン サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
WO2010098429A1 (ja) * 2009-02-27 2010-09-02 国立大学法人大阪大学 免疫アジュバント組成物、及びその利用
EP2711418B1 (en) * 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
WO2015188228A1 (en) * 2014-06-10 2015-12-17 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
BR112017004270B1 (pt) * 2014-09-04 2023-03-07 Stemcell Technologies Inc Método de ativação de células t ou células nk
CA3197849A1 (en) * 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
SG11201708516YA (en) * 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2017087784A1 (en) * 2015-11-18 2017-05-26 Duke University Tumor infiltrating lymphocytes for treatment of cancer
TWI788307B (zh) * 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11261428B2 (en) * 2018-03-15 2022-03-01 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US20200224161A1 (en) * 2017-05-10 2020-07-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
KR20200130826A (ko) * 2018-03-15 2020-11-20 케이에스큐 세러퓨틱스 인코포레이티드 개선된 면역요법을 위한 유전자-조절 조성물 및 방법
CN108753718A (zh) * 2018-06-20 2018-11-06 淮安诺康生物科技有限公司 肿瘤浸润淋巴细胞til的体外扩增方法

Similar Documents

Publication Publication Date Title
Mujal et al. Natural killer cells: from innate to adaptive features
JPWO2021108455A5 (https=)
JP2024041873A5 (https=)
AU2017257225B2 (en) Allele editing and applications thereof
US20230108584A1 (en) Methods for activation and expansion of tumor infiltrating lymphocytes
US20190167720A1 (en) Gene editing for immunological destruction of neoplasia
JP2024020231A5 (https=)
CN116656605A (zh) 用于扩增细胞群的方法、试剂盒及装置
US11022615B2 (en) Regulatory T-cells, method for their isolation and uses
KR20170138560A (ko) 암을 치료하기 위한 방법
JP2023502780A (ja) 腫瘍浸潤リンパ球の活性化及び増殖方法
JPWO2021173964A5 (https=)
JPWO2021050601A5 (https=)
CA2279474C (en) Novel antibody composition for debulking blood and bone marrow samples from cml patients
CN117186228B (zh) 包含长cdr3序列的抗人bcma纳米抗体的双特异性抗体及应用
Hegazy et al. Plasticity and lineage commitment of individual TH1 cells are determined by stable T-bet expression quantities
CN119614577A (zh) 用于细胞靶向和标记的抗cd3核酸适配体
TW200813226A (en) Novel human T cell group
JP7043114B2 (ja) 細胞を活性化させるための方法およびキット
JP2000503672A (ja) 二重特異性抗体断片の簡易化した製造
JP2023516538A (ja) Ｕｃａｒｔ細胞を精製する方法及び応用
CN114853880B (zh) Wt1抗原特异性t细胞受体及其抗肿瘤用途
WO1994025489A1 (en) Downregulation of allergen-specific immune response
McDevitt The role of MHC class II molecules in the pathogenesis and prevention of type I diabetes
KR100734525B1 (ko) 인간 및 비근교계 동물에서 세포독성 ｔ 임파구 활성을효과적으로 측정하는 방법